Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgical Mesh | 19 | 2018 | 50 | 5.360 |
Why?
|
| Urinary Incontinence, Stress | 20 | 2019 | 75 | 5.070 |
Why?
|
| Pelvic Organ Prolapse | 14 | 2020 | 48 | 3.840 |
Why?
|
| Prostatic Hyperplasia | 17 | 2020 | 59 | 2.570 |
Why?
|
| Urinary Bladder, Overactive | 7 | 2020 | 63 | 2.200 |
Why?
|
| Uterine Prolapse | 7 | 2018 | 21 | 1.890 |
Why?
|
| Urinary Incontinence | 6 | 2018 | 68 | 1.870 |
Why?
|
| Suburethral Slings | 6 | 2020 | 14 | 1.850 |
Why?
|
| Urethra | 6 | 2019 | 125 | 1.530 |
Why?
|
| Ablation Techniques | 9 | 2020 | 24 | 1.310 |
Why?
|
| Urodynamics | 8 | 2020 | 88 | 1.250 |
Why?
|
| Biocompatible Materials | 6 | 2014 | 240 | 1.250 |
Why?
|
| Pelvic Floor | 7 | 2017 | 23 | 1.210 |
Why?
|
| Urology | 3 | 2014 | 33 | 1.200 |
Why?
|
| Humans | 74 | 2020 | 32284 | 1.100 |
Why?
|
| Prostatectomy | 7 | 2020 | 85 | 1.060 |
Why?
|
| Prostate | 8 | 2020 | 88 | 1.050 |
Why?
|
| Urologic Diseases | 4 | 2014 | 35 | 1.000 |
Why?
|
| Vagina | 6 | 2020 | 61 | 1.000 |
Why?
|
| Urologic Surgical Procedures | 6 | 2018 | 66 | 0.900 |
Why?
|
| Regenerative Medicine | 3 | 2019 | 216 | 0.850 |
Why?
|
| Prostheses and Implants | 4 | 2018 | 47 | 0.830 |
Why?
|
| Female | 42 | 2020 | 19954 | 0.820 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 317 | 0.820 |
Why?
|
| Prosthesis Failure | 2 | 2015 | 50 | 0.810 |
Why?
|
| Cystitis, Interstitial | 6 | 2020 | 57 | 0.770 |
Why?
|
| Urinary Catheterization | 3 | 2020 | 22 | 0.750 |
Why?
|
| Transurethral Resection of Prostate | 6 | 2020 | 8 | 0.740 |
Why?
|
| Algorithms | 4 | 2018 | 537 | 0.740 |
Why?
|
| Stents | 4 | 2015 | 159 | 0.730 |
Why?
|
| Polypropylenes | 3 | 2012 | 7 | 0.660 |
Why?
|
| Postoperative Complications | 9 | 2020 | 818 | 0.660 |
Why?
|
| Internship and Residency | 3 | 2014 | 317 | 0.640 |
Why?
|
| Tissue Engineering | 2 | 2019 | 695 | 0.620 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2020 | 47 | 0.610 |
Why?
|
| Urinary Bladder Diseases | 3 | 2020 | 44 | 0.610 |
Why?
|
| Reconstructive Surgical Procedures | 4 | 2020 | 191 | 0.590 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2017 | 30 | 0.570 |
Why?
|
| Urinary Bladder | 7 | 2019 | 320 | 0.570 |
Why?
|
| Hydronephrosis | 1 | 2017 | 12 | 0.540 |
Why?
|
| Ureteral Diseases | 1 | 2017 | 8 | 0.540 |
Why?
|
| Treatment Outcome | 17 | 2020 | 3410 | 0.530 |
Why?
|
| Prosthesis Design | 2 | 2015 | 107 | 0.500 |
Why?
|
| Water | 8 | 2020 | 65 | 0.500 |
Why?
|
| Aged | 28 | 2020 | 10257 | 0.480 |
Why?
|
| Exercise Therapy | 2 | 2018 | 249 | 0.460 |
Why?
|
| Urethral Obstruction | 1 | 2015 | 12 | 0.460 |
Why?
|
| Medical Device Recalls | 1 | 2015 | 2 | 0.440 |
Why?
|
| Male | 29 | 2020 | 19434 | 0.430 |
Why?
|
| Public Opinion | 1 | 2014 | 17 | 0.420 |
Why?
|
| Device Removal | 2 | 2012 | 39 | 0.420 |
Why?
|
| Compensation and Redress | 1 | 2013 | 3 | 0.410 |
Why?
|
| Malpractice | 1 | 2013 | 20 | 0.400 |
Why?
|
| Quality of Life | 6 | 2019 | 971 | 0.400 |
Why?
|
| Liability, Legal | 1 | 2013 | 23 | 0.400 |
Why?
|
| Muscle Contraction | 2 | 2018 | 175 | 0.390 |
Why?
|
| Myoblasts | 3 | 2017 | 41 | 0.360 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 17 | 0.350 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 36 | 0.340 |
Why?
|
| Middle Aged | 24 | 2020 | 11843 | 0.330 |
Why?
|
| Collagen | 4 | 2017 | 229 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2014 | 548 | 0.310 |
Why?
|
| Retrospective Studies | 12 | 2020 | 3612 | 0.300 |
Why?
|
| Animals | 12 | 2019 | 8165 | 0.300 |
Why?
|
| Muscarinic Antagonists | 1 | 2009 | 38 | 0.290 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 81 | 0.270 |
Why?
|
| Dietary Proteins | 1 | 2008 | 62 | 0.270 |
Why?
|
| Soybean Proteins | 1 | 2008 | 101 | 0.260 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 3896 | 0.260 |
Why?
|
| Postoperative Hemorrhage | 2 | 2018 | 38 | 0.260 |
Why?
|
| Urethral Diseases | 2 | 2018 | 20 | 0.250 |
Why?
|
| Stroke | 1 | 2012 | 691 | 0.240 |
Why?
|
| Microwaves | 2 | 2008 | 8 | 0.230 |
Why?
|
| Pelvic Pain | 2 | 2017 | 19 | 0.230 |
Why?
|
| Recovery of Function | 2 | 2020 | 236 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 2238 | 0.220 |
Why?
|
| Forecasting | 2 | 2018 | 144 | 0.220 |
Why?
|
| Prevalence | 3 | 2017 | 960 | 0.220 |
Why?
|
| Diathermy | 1 | 2004 | 1 | 0.210 |
Why?
|
| Time Factors | 8 | 2020 | 2196 | 0.210 |
Why?
|
| Organ Size | 6 | 2020 | 221 | 0.210 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 489 | 0.200 |
Why?
|
| Adult | 9 | 2020 | 9263 | 0.200 |
Why?
|
| Peptides | 1 | 2004 | 128 | 0.190 |
Why?
|
| Syndrome | 2 | 2020 | 66 | 0.180 |
Why?
|
| Urethral Stricture | 2 | 2017 | 31 | 0.180 |
Why?
|
| Prospective Studies | 8 | 2020 | 2320 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2017 | 1424 | 0.170 |
Why?
|
| Erectile Dysfunction | 2 | 2018 | 69 | 0.160 |
Why?
|
| Endoscopy | 2 | 2019 | 54 | 0.160 |
Why?
|
| Urinary Retention | 1 | 2020 | 10 | 0.160 |
Why?
|
| Incidence | 2 | 2014 | 1244 | 0.160 |
Why?
|
| Chemokine CXCL12 | 2 | 2018 | 27 | 0.150 |
Why?
|
| Endometriosis | 1 | 2020 | 24 | 0.150 |
Why?
|
| Hospitals | 1 | 2020 | 95 | 0.150 |
Why?
|
| Fibromyalgia | 1 | 2019 | 12 | 0.150 |
Why?
|
| Polyneuropathies | 1 | 2019 | 11 | 0.150 |
Why?
|
| Hydrotherapy | 1 | 2019 | 4 | 0.150 |
Why?
|
| Macaca fascicularis | 4 | 2018 | 542 | 0.140 |
Why?
|
| Anesthesia | 1 | 2019 | 63 | 0.140 |
Why?
|
| Hernia, Inguinal | 1 | 2018 | 4 | 0.140 |
Why?
|
| Pubic Symphysis Diastasis | 1 | 2018 | 3 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2010 | 67 | 0.140 |
Why?
|
| Aging | 3 | 2017 | 941 | 0.140 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2018 | 10 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 30 | 0.140 |
Why?
|
| Patient Positioning | 1 | 2018 | 21 | 0.140 |
Why?
|
| Electric Stimulation Therapy | 1 | 2018 | 19 | 0.140 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 29 | 0.130 |
Why?
|
| Adenoma | 1 | 2018 | 35 | 0.130 |
Why?
|
| Electrocoagulation | 1 | 2018 | 11 | 0.130 |
Why?
|
| Risk Factors | 5 | 2020 | 3938 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2018 | 95 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2017 | 72 | 0.130 |
Why?
|
| Double-Blind Method | 4 | 2020 | 566 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 46 | 0.130 |
Why?
|
| Self Care | 1 | 2018 | 97 | 0.130 |
Why?
|
| Elastin | 2 | 2014 | 16 | 0.130 |
Why?
|
| Behavior Therapy | 1 | 2018 | 103 | 0.130 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 40 | 0.130 |
Why?
|
| RNA | 2 | 2016 | 94 | 0.130 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 230 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 212 | 0.120 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2017 | 368 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 100 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 502 | 0.120 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 130 | 0.110 |
Why?
|
| United States | 2 | 2014 | 4079 | 0.110 |
Why?
|
| Gene Expression | 1 | 2016 | 345 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2015 | 51 | 0.110 |
Why?
|
| Frail Elderly | 1 | 2015 | 69 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 851 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 1073 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 51 | 0.100 |
Why?
|
| Cystocele | 2 | 2017 | 4 | 0.100 |
Why?
|
| Internet | 1 | 2014 | 202 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 47 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2014 | 178 | 0.090 |
Why?
|
| Extracellular Matrix | 2 | 2011 | 255 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 478 | 0.090 |
Why?
|
| Cadaver | 2 | 2016 | 151 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 38 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 19 | 0.080 |
Why?
|
| Regeneration | 1 | 2011 | 178 | 0.080 |
Why?
|
| Credentialing | 1 | 2009 | 7 | 0.080 |
Why?
|
| Benzofurans | 1 | 2009 | 3 | 0.070 |
Why?
|
| Pyrrolidines | 1 | 2009 | 15 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 219 | 0.070 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 106 | 0.070 |
Why?
|
| Cystectomy | 1 | 2010 | 109 | 0.070 |
Why?
|
| Carbachol | 1 | 2008 | 17 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2008 | 8 | 0.070 |
Why?
|
| Phenylephrine | 1 | 2008 | 34 | 0.070 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 42 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 154 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 272 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 60 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 238 | 0.070 |
Why?
|
| Hematuria | 1 | 2008 | 10 | 0.070 |
Why?
|
| Tissue Scaffolds | 1 | 2011 | 431 | 0.070 |
Why?
|
| Random Allocation | 1 | 2008 | 246 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2008 | 202 | 0.070 |
Why?
|
| Robotics | 1 | 2009 | 133 | 0.070 |
Why?
|
| Biological Products | 1 | 2009 | 79 | 0.070 |
Why?
|
| Muscle, Smooth | 1 | 2008 | 152 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 189 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2008 | 81 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 555 | 0.060 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 2 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 544 | 0.060 |
Why?
|
| Suture Techniques | 1 | 2007 | 60 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 1052 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 309 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 200 | 0.060 |
Why?
|
| Primates | 2 | 2017 | 128 | 0.060 |
Why?
|
| Phenotype | 2 | 2020 | 619 | 0.060 |
Why?
|
| Prolapse | 1 | 2005 | 5 | 0.060 |
Why?
|
| Fascia | 1 | 2005 | 9 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2007 | 123 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 298 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2007 | 184 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 312 | 0.050 |
Why?
|
| Collagen Type III | 1 | 2004 | 9 | 0.050 |
Why?
|
| Pyridinium Compounds | 1 | 2004 | 5 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2004 | 18 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2004 | 44 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 411 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 554 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 151 | 0.050 |
Why?
|
| Pelvis | 2 | 2018 | 67 | 0.050 |
Why?
|
| Adolescent | 3 | 2019 | 3521 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2004 | 417 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 2652 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 42 | 0.040 |
Why?
|
| Anesthetics | 1 | 2019 | 21 | 0.040 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2018 | 4 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 2018 | 11 | 0.040 |
Why?
|
| Perineum | 1 | 2018 | 17 | 0.040 |
Why?
|
| Prostatism | 1 | 2018 | 4 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 11 | 0.030 |
Why?
|
| Ejaculation | 1 | 2018 | 7 | 0.030 |
Why?
|
| Endosonography | 1 | 2018 | 55 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 19 | 0.030 |
Why?
|
| Hernia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Compliance | 1 | 2017 | 14 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 321 | 0.030 |
Why?
|
| Pressure | 1 | 2017 | 69 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 98 | 0.030 |
Why?
|
| Social Behavior | 1 | 2017 | 69 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 34 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 184 | 0.030 |
Why?
|
| Urine | 1 | 2017 | 69 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2016 | 108 | 0.030 |
Why?
|
| Color | 1 | 2015 | 12 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 59 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 50 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 69 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 323 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 16 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 20 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2014 | 27 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 249 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1211 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 8 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 49 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 821 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 185 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 69 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 75 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2009 | 329 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2007 | 79 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 6 | 0.010 |
Why?
|
| Abdomen | 1 | 2004 | 44 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 118 | 0.010 |
Why?
|
| Urethral Neoplasms | 1 | 2003 | 5 | 0.010 |
Why?
|
| Metaplasia | 1 | 2003 | 20 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 25 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 287 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 177 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 906 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 214 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 821 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 858 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 156 | 0.010 |
Why?
|